Kalydeco Marks the Latest Success of the Cystic Fibrosis Foundation’s Venture Philanthropy Model
Site Search
Aim is to Provide Cystic Fibrosis Patients Enhanced Access to Medications and Expanded Pharmacy Services
CF Foundation Provided Scientific, Clinical and Significant Funding Support in Drug Development Process
This medicine represents the single greatest therapeutic advancement in the history of CF, offering a treatment for the underlying cause of the disease that could eventually benefit more than 90 percent of people with CF.
Update: On February 3, 2017, the Cystic Fibrosis Foundation divested its remaining ownership stake in CF Services Inc., a specialty pharmacy. The pharmacy is now fully owned by Walgreens.
Managing cystic fibrosis can feel overwhelming at times — but we’re here to help. Learn how to navigate life with CF.
Drug Targets the Underlying Cause of the Disease in People with the Most Common CF Mutation